Enbrace Hr

Levomefolate Magnesium, Leucovorin, Folic Acid, Ferrous Cysteine Glycinate, Magnesium Ascorbate, Zinc Ascorbate, Cocarboxylase, Flavin Adenine Dinucleotide, Nadh, Pyridoxal Phosphate Anhydrous, Cobamamide, Betaine, Magnesium L-threonate, 1,2-docosahexanoyl-sn-glycero-3-phosphoserine Calcium, 1,2-icosapentoyl-sn-glycero-3-phosphoserine Calcium, And Phosphatidyl Serine


Jaymac Pharma
Human Prescription Drug
NDC 64661-650
Enbrace Hr also known as Levomefolate Magnesium, Leucovorin, Folic Acid, Ferrous Cysteine Glycinate, Magnesium Ascorbate, Zinc Ascorbate, Cocarboxylase, Flavin Adenine Dinucleotide, Nadh, Pyridoxal Phosphate Anhydrous, Cobamamide, Betaine, Magnesium L-threonate, 1,2-docosahexanoyl-sn-glycero-3-phosphoserine Calcium, 1,2-icosapentoyl-sn-glycero-3-phosphoserine Calcium, And Phosphatidyl Serine is a human prescription drug labeled by 'Jaymac Pharma'. National Drug Code (NDC) number for Enbrace Hr is 64661-650. This drug is available in dosage form of Capsule, Delayed Release Pellets. The names of the active, medicinal ingredients in Enbrace Hr drug includes 1,2-docosahexanoyl-sn-glycero-3-phosphoserine Calcium - 6.4 mg/1 1,2-icosapentoyl-sn-glycero-3-phosphoserine Calcium - 800 ug/1 Betaine - 500 ug/1 Cobamamide - 50 ug/1 Cocarboxylase - 25 ug/1 Ferrous Cysteine Glycinate - 13.6 mg/1 Flavin Adenine Dinucleotide - 25 ug/1 Folic Acid - 1 mg/1 Leucovorin - 2.5 mg/1 Levomefolate Magnesium - 5.23 mg/1 and more. The currest status of Enbrace Hr drug is Active.

Drug Information:

Drug NDC: 64661-650
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Enbrace Hr
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Levomefolate Magnesium, Leucovorin, Folic Acid, Ferrous Cysteine Glycinate, Magnesium Ascorbate, Zinc Ascorbate, Cocarboxylase, Flavin Adenine Dinucleotide, Nadh, Pyridoxal Phosphate Anhydrous, Cobamamide, Betaine, Magnesium L-threonate, 1,2-docosahexanoyl-sn-glycero-3-phosphoserine Calcium, 1,2-icosapentoyl-sn-glycero-3-phosphoserine Calcium, And Phosphatidyl Serine
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Jaymac Pharma
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Capsule, Delayed Release Pellets
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:1,2-DOCOSAHEXANOYL-SN-GLYCERO-3-PHOSPHOSERINE CALCIUM - 6.4 mg/1
1,2-ICOSAPENTOYL-SN-GLYCERO-3-PHOSPHOSERINE CALCIUM - 800 ug/1
BETAINE - 500 ug/1
COBAMAMIDE - 50 ug/1
COCARBOXYLASE - 25 ug/1
FERROUS CYSTEINE GLYCINATE - 13.6 mg/1
FLAVIN ADENINE DINUCLEOTIDE - 25 ug/1
FOLIC ACID - 1 mg/1
LEUCOVORIN - 2.5 mg/1
LEVOMEFOLATE MAGNESIUM - 5.23 mg/1
MAGNESIUM ASCORBATE - 24 mg/1
MAGNESIUM L-THREONATE - 1 mg/1
NADH - 25 ug/1
PHOSPHATIDYL SERINE - 12 mg/1
PYRIDOXAL PHOSPHATE ANHYDROUS - 25 ug/1
ZINC ASCORBATE - 1 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 12 Aug, 2011
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Jaymac Pharma
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0364661650302
UPC stands for Universal Product Code.
NUI:N0000175804
N0000175805
N0000178369
M0008658
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:6WJM73T46K
9ABD9DRK7B
3SCV180C9W
F0R1QK73KB
Q57971654Y
8B4OP7RK5N
ZC44YTI8KK
935E97BOY8
Q573I9DVLP
1VZZ62R081
0N1G678593
1Y26ZZ0OTM
4J24DQ0916
394XK0IH40
F06SGE49M6
9TI35313XW
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:Methylating Activity [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:Methylating Agent [EPC]
Folate Analog [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Folic Acid [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Ascorbic Acid [CS]
Folate Analog [EPC]
Folic Acid [CS]
Methylating Activity [MoA]
Methylating Agent [EPC]
Vitamin C [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
64661-650-3030 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE (64661-650-30)12 Aug, 2011N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Enbrace hr levomefolate magnesium, leucovorin, folic acid, ferrous cysteine glycinate, magnesium ascorbate, zinc ascorbate, cocarboxylase, flavin adenine dinucleotide, nadh, pyridoxal phosphate anhydrous, cobamamide, betaine, magnesium l-threonate, 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium, 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium, and phosphatidyl serine levomefolate magnesium levomefolic acid leucovorin leucovorin folic acid folic acid ferrous cysteine glycinate ferrous cation magnesium ascorbate ascorbic acid zinc ascorbate ascorbic acid cocarboxylase cocarboxylase flavin adenine dinucleotide flavin adenine dinucleotide nadh nadh pyridoxal phosphate anhydrous pyridoxal phosphate anhydrous cobamamide cobamamide betaine betaine magnesium l-threonate threonic acid, dl- 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium 1,2-docosahexanoyl-sn-glycero-3-phosphoserine 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium 1,2-icosapentoyl-sn-glycero-3-phosphoserine phosphatidyl serine phosphatidyl serine annatto gelatin lecithin, sunflower piperine water ubidecarenone yellow wax annatto oval enl

Indications and Usage:

Indications: enbrace® hr is indicated in the treatment of vitamin deficiency - specifically vitamin b 12 deficiency, and the prevention of vitamin b 12 -cofactor deficiency, l-methylfolate. requirements of vitamin b 9 and/or vitamin b 12 in excess of normal due to pregnancy can usually be met with oral supplementation.

Dosage and Administration:

Dosage and administration ​: the adult dose is one capsule daily preferably on an empty stomach . as a general rule reticulocyte plasma count, folate and vitamin b 12 status must be obtained prior to treatment. do not exceed recommended dose. call your medical practitioner about side effects. you may report side effects by calling 337.662-5962.

Adverse Reactions:

Adverse reactions: mild transient diarrhea, polycythemia vera, itching, transitory exanthema, feeling of swelling of entire body may occur with administration of vitamin b 12 . allergic sensitization has been reported following both oral and parenteral administration of folic acid.

Description:

Description: enbrace® hr is an orally administered prescription prenatal vitamin for therapeutic use formulated for adult patients who are under specific and directr monitoring of a licensed medical practitioner. enbrace® hr contains a small amount of iron and may be taken concurrently with iron supplementation. ​ingredients: control-release, citrated folic acid, dhf+ (b 9 - provitamin) 1 mg ​1 vitamin b 12 [cobamamide] 50 mcg ​2 fegc [ferrous glycine cysteinate] (1.5 mg elemental iron) 13.6 mg ​3 also contains: folinic acid (b 9 -vitamer) 2.5 mg ​1 levomefolic acid (b 9 & b 12 - cofactor) 5.23 mg ​4 1 6 mg dfe folate (vitamin b 9 ) 2 the form most found in mammalian liver - adjusted for stability and ph in the presence of stomach substance, is a cobamamide, or vitamin b 12 3 pure amino acid, cysteinated iron chelate as aminofertm* under exclusive license 4 9 mg dfe l-methylfolate magnesium (molar equivalent) * aminofertm (viva pharmaceuticals, canada) u.s. patent # 7,341,708

Mechanism of Action:

Mechanism of action: vitamin b 12 [ treatment ]; folate [ prevention ]; other [ supplementation ];

How Supplied:

How supplied: oval, brownish-orange softgel capsule with imprint enl .

Package Label Principal Display Panel:

Principal display panel: enbrace hr ™ with deltafolate tm ndc 64661- 650 -30 rx only certified 3rd-party gluten-free [15 mg dfe folate] [50 mcg cbi][1.5 mg fegc] anti-anemia preparation low-iron jaymac pharmaceuticals, llc softgel (30 ct bottle) prescription prenatal vitamin for therapeutic use enbrace-label image


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.